Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Classical hematology 2Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 12Myelodysplastic Syndromes 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myelomonocytic, Chronic 5Primary Myelofibrosis 2Multiple Myeloma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Graft vs Host Disease 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Non-Malignant Neoplasm 1Neuroblastoma 1Myeloproliferative Disorders 1Motor Activity 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Ganglioneuroblastoma 1

Interventions

Cyclophosphamide 15fludarabine phosphate 11fludarabine 11Whole-Body Irradiation 11Mycophenolic Acid 11Busulfan 9Melphalan 8Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Azacitidine 5Filgrastim 4venetoclax 3Cord Blood Stem Cell Transplantation 3Biopsy 3thymoglobulin 2decitabine and cedazuridine drug combination 2Vorinostat 2Thiotepa 2Specimen Handling 2Sirolimus 2Rituximab 2Methotrexate 2Injections 2Hematopoietic Stem Cell Transplantation 2Etoposide 2Cytarabine 2Cyclosporins 2Clofarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × Hematopoietic Stem Cell Transplantation × 1 year × Clear all
NCT07249346 2025-12-24

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
124 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Leukemia, Myelomonocytic, Chronic

NCT03314974 2025-06-24

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
300 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Leukemia, Plasma Cell, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡